Drugs / SGM-1019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03676231 | Jan → May 2019 | metabolic dysfunction-associated steatohepatitis | Second Genome | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGM-1019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03676231 ↗ |